KaydedilenlerDerginizi ekleyin

Dergiler / Dicle Tıp Dergisi / 2026 / Cilt: 46 Sayı: 2

Primer Plazma Hücreli Lösemi: Olgu Sunumu

Sinan Demircioğlu0000-0003-1277-5105
Ali Doğan0000-0003-0207-3505
Murat Altınbaşak0000-0001-9058-1424
Cengiz Demir0000-0001-9856-184X
Sayfa
393–396
Yayın Tarihi
2019-06-11
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Tedavide bortezomib bazlı rejimler ve otolog kök hücre nakli önerilmektedir. 

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Plazma hücreli lösemi (PHL), plazma hücreli diskrazilerin nadir görülen bir formudur.
📊
Temel Bulgular & Veri:Primer ve sekonder PHL olmak üzere iki formu vardır.
💡
Sonuç & Katkı:Tedavide bortezomib bazlı rejimler ve otolog kök hücre nakli önerilmektedir. 
🔬Tür:Olgu Sunumu
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Morfoloji · multiple myelom · plazma hücreli lösemi

Özet

Plazma hücreli lösemi (PHL), plazma hücreli diskrazilerin nadir görülen bir formudur. Primer ve sekonder PHL olmak üzere iki formu vardır. Prognozu oldukça kötüdür. Morfolojik olarak matür plazma hücrelerine benzememesi sebebiyle tanıda karışıklıklar olabilmektedir. Tedavide bortezomib bazlı rejimler ve otolog kök hücre nakli önerilmektedir. 

🔖

Bu Makaleye Atıf Yap

Demircioğlu, S., Doğan, A., Altınbaşak, M., Demir, C. (2019). Primer Plazma Hücreli Lösemi: Olgu Sunumu. Dicle Tıp Dergisi, Cilt: 46 Sayı: 2, 393–396. https://doi.org/10.5798/dicletip.575025

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (22)

  1. Sant M, Allemani C, Tereanu C, et all. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-34.2. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. The American journal of medicine 1987; 83: 1062-8.
  2. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et all. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044-52.
  3. Fernandez de Larrea C, Kyle RA, Durie BG, et all. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27: 780-91.
  4. Garcia-Sanz R, Orfao A, Gonzalez M, et all. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032-7.
  5. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305-10.
  6. Kyle RA, Gertz MA, Witzig TE, et all. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
  7. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998; 30: 493-501.
  8. Gonsalves WI, Rajkumar SV, Go RS, et all. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014; 124: 907-12.
  9. Musto P. Progress in the Treatment of Primary Plasma Cell Leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 2082-4.
  10. Musto P, Simeon V, Martorelli MC, et all. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 2014; 28: 222-5.
  11. Royer B, Minvielle S, Diouf M, et all. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 2125-32.
  12. Jung SH, Lee JJ, Kim K, et all. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget 2017; 8: 79517-26.
  13. Granell M, Calvo X, Garcia-Guinon A, et all. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 2017; 102: 1099-104.
  14. D'Arena G, Valentini CG, Pietrantuono G, et all. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012; 23: 1499-502.
  15. Katodritou E, Terpos E, Kelaidi C, et all. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. American journal of hematology 2014; 89: 145-50.
  16. Lebovic D, Zhang L, Alsina M, et all. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clinical lymphoma, myeloma & leukemia 2011; 11: 507-11.
  17. van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood 2012; 120: 2376-89.
  18. Mahindra A, Kalaycio ME, Vela-Ojeda J, et all. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012; 26: 1091-7.
  19. Nishihori T, Abu Kar SM, Baz R, et all. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 2013; 19: 1144-51.
  20. Chim CS, Kumar SK, Orlowski RZ, et all. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 2018; 32: 252-62.
  21. Royer B, Minvielle S, Diouf M, et all. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 2125-32.
  22. Nishihori T, Abu Kar SM, Baz R, et all. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 2013; 19: 1144-51.